EUCTR2008-003869-72-PT进行中（未招募）不适用
A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO INVESTIGATE THE TOLERABILITY AND EFFECT OF THREE SINGLE-DOSE REGIMENS OF BIA 9-1067 ON THE LEVODOPA PHARMACOKINETICS, MOTOR RESPONSE, AND ERYTHROCYTE SOLUBLE CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN PARKINSON'S DISEASE PATIENTS CONCOMITANTLY TREATED WITH LEVODOPA/DOPA-DECARBOXYLASE INHIBITOR
Bial - Portela & Cª, S.A.0 个研究点目标入组 12 人开始时间: 2008年6月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female of non-childbearing potential (by reason of surgery or postmenopausal) aged between 30 and 75 years, inclusive; a diagnosis of PD according to the UK PDS Brain Bank diagnostic criteria (bradykinesia and at least one of the following: muscular rigidity, rest tremor and postural instability); predictable signs of end-of-dose deterioration despite optimal” levodopa/carbidopa or levodopa/benserazide therapy; been treated with a stable regimen of 3 to 8 doses of standard release levodopa/carbidopa 100/25 mg or levodopa/benserazide 100/25 mg per day within at least 1 week prior to randomisation; modified Hoehn and Yahr stage of less than 5 in the off-state; mean duration of OFF stage =1.5 h during waking hours (based on historical information); concomitant anti-Parkinsonian medication (other than apomorphine, entacapone or tolcapone) in stable doses for at least 4 weeks prior to randomisation; results of clinical laboratory tests acceptable by the investigator (not clinically significant for the well-being of the patient or for the purpose of the study); able and willing to give written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Non-idiopathic parkinsonism (atypical parkinsonism, symptomatic parkinsonism, Parkinson-plus syndrome); treated with levodopa/carbidopa or levodopa/benserazide in a 10:1 ratio, or with levodopa/carbidopa in a controlled-release formulation; treated with entacapone, tolcapone, neuroleptics, antidepressants (except serotonin-specific reuptake inhibitors or imipraminics [desipramine, imipramine, clomipramine and amitriptyline]), monoamine oxidase inhibitors (except selegiline up to 10 mg/day in oral formulation or 1.25 mg/day in buccal absorption formulation or rasagiline up to 1 mg/day) or antiemetics (except domperidone) within 4 weeks prior to randomisation; treated with apomorphine within 7 days prior to randomisation; treated with any investigational product within 2 months prior to randomisation (or within 5 half-lives, whichever is longer); a psychiatric or any medical condition that might place him/her at increased risk or interfere with assessments; known hypersensitivity to any of the ingredients of the investigational products; a history of abuse of alcohol, drugs or medications within the last 2 years; a clinically relevant ECG abnormality; a history or current evidence of heart disease, including but not limited to myocardial infarction, angina, congestive heart failure and cardiac arrhythmia; unstable concomitant disease being treated with changing doses of medication; a history or current evidence of any relevant disease in the context of this study, i.e., with respect to the safety of the patient (e.g., hepatic or renal impairment) or related to the study conditions; a test positive for the human immunodeficiency viruses (HIV) 1 or 2 antibodies, or hepatitis B surface antigen (HbsAg), or hepatitis C antibody (HCVAb); donated blood or received blood or blood products within the 6 months prior to randomisation; pregnant, breast-feeding or of childbearing potential; other condition or circumstance that, in the opinion of the investigator, may compromise the patient’s ability to comply with the study protocol.
研究者
相似试验
进行中（未招募）
1 期
A RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND, CROSS-OVER, MONOCENTER STUDY TO EVALUATE THE EFFECT OF A 7-DAY MONTELUKAST TREATMENT ON AIRWAY INFLAMMATION AND FUNCTION BY MEANS OF BRONCHOPROVOCATION WITH ADENOSINE-5’-MONOPHOSPHATE IN PATIENTS WITH MILD OR MODERATE ALLERGIC ASTHMA - M/MTAST/01Mild to moderate asthma according to GINA (Global initiative for Asthma, 2004) guidelines.EUCTR2006-000334-12-DEAlmirall Prodesfarma18
已完成
不适用
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, CROSS-OVER, ASCENDING SINGLE ORAL DOSE, SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF CB-189,625 IN HEALTHY MALE SUBJECTS.acute en chronische pijnacute and chronic painNL-OMON37794Cubist Pharmaceuticals, Inc18
进行中（未招募）
1 期
A study to find out if orvepitant is safe to use and reduces the severity of cough in patients with idiopathic pulmonary fibrosisChronic cough in patients with idiopathic pulmonary fibrosisMedDRA version: 21.1Level: LLTClassification code 10066656Term: Chronic coughSystem Organ Class: 100000004855EUCTR2021-006278-22-NLeRRe Therapeutics Ltd108
进行中（未招募）
1 期
STUDY WITH RANDOM DISTRIBUTION OF TREATMENTS (THREE DIFFERENT DOSES OF FASITIBANT AND PLACEBO), WHERE NEITHER THE INVESTIGATOR NOR THE PATIENT KNOWS THE TREATMENT TAKEN, TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND THE EFFECTS OF THE DRUG WHEN INJECTED INTO THE KNEE JOINT IN PATIENTS WITH OSTEARTHRITIS OF THE KNEE.Symptomatic osteoarthritis (OA) of the knee.MedDRA version: 17.0Level: SOCClassification code 10028395Term: Musculoskeletal and connective tissue disordersSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-004999-35-CZMenarini Ricerche S.p.A.440
进行中（未招募）
不适用
STUDY WITH RANDOM DISTRIBUTION OF TREATMENTS (THREE DIFFERENT DOSES OF FASITIBANT AND PLACEBO), WHERE NEITHER THE INVESTIGATOR NOR THE PATIENT KNOWS THE TREATMENT TAKEN, TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND THE EFFECTS OF THE DRUG WHEN INJECTED INTO THE KNEE JOINT IN PATIENTS WITH OSTEARTHRITIS OF THE KNEE.Symptomatic osteoarthritis (OA) of the knee.MedDRA version: 16.1Level: LLTClassification code 10023476Term: Knee osteoarthritisSystem Organ Class: 100000004859EUCTR2013-004999-35-ITMenarini Ricerche S.p.A.440